10.4.2026 09:51:08 CEST | Thor Medical ASA | Additional regulated information
required to be disclosed under the laws of a member state
9 April 2026 | Thor Medical ASA | Additional regulated information required to
be disclosed under the laws of a member state
The nomination committee has made its recommendation to the Annual General
Meeting of Thor Medical ASA that will be held on 23 April 2026, at 14:00 hours
CEST at Advokatfirmaet Selmer, Ruseløkkveien 14, 0251 Oslo. The recommendation
and the previously distributed notice are not fully aligned, and the company
wishes to clarify that the proposed resolutions for the general meeting are as
set out in the nomination committee's recommendation with respect to the matters
it concerns.
The recommendation of the nomination committee is attached and is also available
on www.thormedical.com - https://www.thormedical.com.
For further information please contact:
Mathias Nilsen Reierth
Head of Communications and Corporate Affairs
Tel: +47 988 05 724
mathias.reierth@thormedical.com
ABOUT THOR MEDICAL ASA
Thor Medical is an emerging supplier of radionuclides, primarily alpha particle
emitters, from naturally occurring thorium. Its proprietary production process
requires no irradiation or use of nuclear reactors, and provides reliable,
environmentally friendly, cost-efficient supply of alpha-emitters for the
radiopharmaceutical industry. Thor Medical is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange under the ticker symbol 'TRMED'.
To learn more, visit www.thormedical.com - http://www.thormedical.com
DISCLOSURE REGULATION
This information is required to be disclosed under Section 5-12 of the
Securities Trading Act.
ATTACHMENTS
a4feec3c-84ad-4bec-b2e1-e467204eb501.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18858270/7031/a4feec3c-84ad-4bec-
b2e1-e467204eb501.pdf
Thor Medical - Nomination Committee proposal 2026.pdf -
https://kommunikasjon.ntb.no/ir-files/17848634/18858270/7030/Thor%20Medical%20-%
20Nomination%20Committee%20proposal%202026.pdf